This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jay S. Duker, MD; Paul Ashton, PhD
Boston, Mass

Janet L. Davis, MD; Robert Keller, MD
Miami, Fla

Elaine Chuang, MD
Seattle, Wash

Arch Ophthalmol. 1996;114(7):881-882.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

A sustained-release, intravitreal implant that supplies ganciclovir directly into the vitreous cavity at a constant rate for approximately 8 months is being tested.^1,2 We report the use of multiple ganciclovir implants for the long-term (>3 years) maintenance of cytomegalovirus (CMV) retinitis. Excellent local CMV retinitis control was achieved, even when follow-up exceeded 3 years.

Report of a Case.

In late December 1991, a 33-year-old man with acquired immunodeficiency syndrome was examined; unilateral, peripheral CMV retinitis was diagnosed in the right eye. His visual acuity was 20/20 OU. The CD4 count was 0.003x10⁹L.

After administration of intravenous ganciclovir sodium (390 mg), given twice daily for 2 weeks, a positive clinical response was noted (Figure 1). The patient underwent ganciclovir implantation on January 29, 1992; a modification of a previously reported technique was used.² The administration of intravenous ganiclovir was discontinued on the day of the implantation. By 4 weeks after implantation, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?